First-Line PARP Inhibitors—Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis

First-Line PARP Inhibitors—Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis

Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) 1 and 2, has been shown to improve progression free survival in patients when used as maintenance treatment after first-line platinum-based chemotherapy in advanced stage (III to IV) high-grade ovarian cancer, and after platinum-bas...

Full description

Bibliographic Details
Main Authors: Alistair McLaren, Douglas Cartwright, Ewen Ross, Patricia Roxburgh
Format: Article
Language:English
Published: Innovative Healthcare Institute 2021-08-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
parpi
niraparib
pneumonitis
case report
Online Access:https://jipo.org/doi/pdf/10.36401/JIPO-20-33

Internet

https://jipo.org/doi/pdf/10.36401/JIPO-20-33

Similar Items